```html

Extravasation of Fluid

What is Extravasation of Fluid?

Extravasation of fluid refers to the accidental leakage of a fluid—usually a medication, contrast agent, or blood—out of a blood vessel or catheter and into the surrounding tissue. The term “extravasation” comes from Latin “extra‑” (outside) and “vas” (vessel). While a small amount of fluid might cause only mild swelling, larger volumes can lead to pain, inflammation, tissue damage, or even necrosis if not recognized promptly.

The phenomenon is most commonly seen in the context of intravenous (IV) therapy, chemotherapy infusion, or radiologic contrast administration, but it can also occur after a traumatic injury or during surgical procedures when a vessel is breached.

Key point: Extravasation is not simply “swelling”; it is the **outside‑the‑vessel** movement of fluid that can be irritant or toxic to the tissues it contacts.

Common Causes

Below are the most frequent situations that lead to extravasation. Understanding these helps patients and clinicians stay vigilant.

• IV medication infusions – especially vesicant or irritant drugs such as chemotherapy agents (e.g., doxorubicin, vincristine), vasopressors, and certain antibiotics.
• Radiologic contrast administration – iodinated or gadolinium‑based agents used in CT, MRI, or fluoroscopy can leak from the cannula.
• Blood transfusion – improper catheter placement or high infusion pressure can force blood into surrounding tissue.
• Peripheral IV catheter dislodgement – movement of the catheter tip out of the vessel lumen.
• Infiltration during fluid therapy – routine saline, lactated Ringer’s, or dextrose solutions may infiltrate when veins are fragile.
• Traumatic vascular injury – needle puncture, blunt trauma, or surgical manipulation that tears a vessel wall.
• High‑pressure infusion devices – powered pumps or pressure bags that exceed the vein’s capacity.
• Pediatric and geriatric patients – thin, delicate veins make them more susceptible.
• Improper technique – inadequate securing of the catheter, failure to rotate sites, or using too large a gauge.
• Underlying venous disease – thrombophlebitis, sclerotic veins, or previous catheterizations increase risk.

Associated Symptoms

Symptoms can range from subtle to severe, often developing within minutes to several hours after the infusion starts.

• Localized swelling or puffiness at the infusion site
• Warmth or heat sensation
• Pain or burning that may become sharp or throbbing
• Redness or a bluish‑purple discoloration
• Skin tightening or a “firm” feeling (indicating edema)
• Blistering or skin breakdown in severe cases
• Decreased or absent distal pulse if large volume extravasates
• Extended range of motion limitation due to discomfort
• Systemic signs (rare) – fever, chills, or signs of infection if the fluid becomes contaminated

When to See a Doctor

Because tissue injury can progress quickly, early medical evaluation is crucial. Seek professional help if you notice any of the following:

• Rapid increase in swelling or pain that does not improve after stopping the infusion.
• Skin changes such as blisters, ulceration, or a darkening discoloration.
• Persistent burning sensation despite removing the IV line.
• Loss of sensation, numbness, or tingling around the site.
• Difficulty moving the affected limb or joint.
• Fever, chills, or drainage suggestive of infection.
• Any concern after receiving a known vesicant chemotherapy drug.

Even if symptoms seem mild, reporting them promptly can prevent long‑term complications such as scarring or functional loss.

Diagnosis

Healthcare providers use a combination of clinical assessment and, when needed, imaging studies to confirm extravasation and gauge its severity.

Clinical Examination

• Visual inspection – looking for swelling, erythema, skin discoloration, and blister formation.
• Palpation – assessing temperature, firmness, and tenderness.
• Functional testing – checking range of motion and distal neurovascular status (pulses, sensation).

Imaging (when indicated)

• Ultrasound – can delineate the fluid collection size and rule out deep vein thrombosis.
• Fluoroscopy or X‑ray – occasionally used during contrast studies to locate leaked contrast.
• CT or MRI – reserved for extensive cases where there is suspicion of compartment syndrome or deep tissue involvement.

Laboratory Tests

• Baseline blood counts and inflammatory markers (e.g., CRP) if infection is suspected.
• Renal function tests may be checked after large‑volume contrast extravasation.

Treatment Options

Management depends on the type of fluid, volume extravasated, and time since onset. Prompt action can limit tissue injury.

Immediate Steps (first‑aid)

• Stop the infusion immediately. Do not restart the same line.
• Leave the catheter in place. It can be used to aspirate the leaked fluid.
• Elevate the extremity above heart level to reduce swelling.
• Apply a cold compress (for vesicant drugs or contrast) for the first 15–20 minutes, then switch to warm compresses after 2–3 hours if the fluid is non‑vesicant (per institutional protocol).
• Document the exact location, size of the area, and any patient‑reported symptoms.

Medical Interventions

• Aspiration – using a syringe attached to the existing catheter to withdraw as much fluid as possible.
• Antidote administration – specific agents such as hyaluronidase (for hyaluronic‑acid‑based fillers) or sodium thiosulfate (for certain chemotherapeutics) can be injected around the site.
• Topical or systemic steroids – may reduce inflammation, especially after chemotherapy extravasation.
• Analgesia – NSAIDs or acetaminophen for pain control; opioids for severe pain.
• Antibiotics – only if secondary infection is evident.
• Physical therapy – gentle range‑of‑motion exercises to prevent stiffness once acute pain subsides.
• Surgical debridement – rare, reserved for extensive necrosis or compartment syndrome.

Home Care (after professional evaluation)

• Continue gentle elevation of the limb for 24‑48 hours.
• Apply warm compresses (if advised) 3–4 times daily for 20 minutes to promote resorption.
• Monitor the area for increasing redness, swelling, or drainage.
• Take prescribed pain medication as directed; avoid NSAIDs if you have kidney disease or are on certain chemotherapy regimens.
• Keep the site clean and dry; change dressings according to the provider’s instructions.
• Follow up with the infusion nurse or oncologist within 24–48 hours, or sooner if symptoms worsen.

Prevention Tips

Most extravasation events are preventable with proper technique and patient education.

• Choose appropriate vein size – use a vein that matches or exceeds the catheter gauge.
• Secure the catheter with adhesive dressings and avoid excessive movement of the limb.
• Rotate infusion sites – no more than 72‑hour use of the same peripheral site.
• Use infusion pumps with pressure alarms to detect occlusion early.
• Educate patients on early signs (tightness, tingling) and encourage them to speak up immediately.
• Limit infusion rate for vesicant drugs; follow manufacturer recommendations.
• Apply a transparent dressing so visual inspection is easy.
• For high‑risk patients (children, elderly, chemotherapy recipients), consider central venous access devices when long‑term therapy is needed.
• Regularly assess the IV site during the infusion—every 15‑30 minutes for vesicants, every hour for non‑vesicants.
• Document any infiltration promptly; use a standardized reporting form to improve institutional learning.

Emergency Warning Signs

References

1. Mayo Clinic. “Extravasation (IV Infiltration).” Accessed June 2026. https://www.mayoclinic.org
2. Cleveland Clinic. “Chemotherapy Extravasation Management.” 2024. https://my.clevelandclinic.org
3. National Cancer Institute. “Management of Chemotherapy Extravasation.” 2023. https://www.cancer.gov
4. American Society of Radiologic Technologists. “Contrast Media Extravasation.” 2022. https://www.asrt.org
5. World Health Organization. “Safety in Intravenous Therapy.” WHO Guidelines, 2021. https://www.who.int
6. American Society of Clinical Oncology. “Guidelines for the Prevention and Management of Chemotherapy‑Induced Extravasation.” 2022.
7. National Institute for Health and Care Excellence (NICE). “Intravenous Extravasation and Infiltration.” NG191, 2023.

```